A New Form of Specific Targeting Cancer Immunotherapy Using Anti‐tumor Monoclonal Antibody‐conjugated Lymphokine‐activated Killer Cells

Cross‐linking of effector T cells to target cancer cells augments their tumor lytic activities. Here we describe a new method of conjugating lymphokine‐activated killer (LAK) cells with cancer‐specific monoclonal antibody. The LAK cells were biotinylated, treated with avidin, and conjugated with bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiraiwa, Hiroshi, Sekine, Teruaki, Tobisu, Ken‐ichi, Kakizoe, Tadao, Koiso, Kenkichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1991
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://www.ncbi.nlm.nih.gov/pubmed/1906847
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918496/
https://www.ncbi.nlm.nih.gov/pubmed/1906847
http://dx.doi.org/10.1111/j.1349-7006.1991.tb01895.x

Ejemplares similares